Tag: rare disease trials China

Rare Disease Trials in China: Regulatory Pathways

Posted on digi By digi

Rare Disease Trials in China: Regulatory Pathways Regulatory Pathways for Rare Disease Clinical Trials in China Introduction Rare diseases affect an estimated 20 million people in China, yet historically these patients had limited access to innovative therapies. Clinical trials for rare diseases face unique challenges, including small patient populations, recruitment barriers, and limited disease registries….

Read More “Rare Disease Trials in China: Regulatory Pathways” »

Clinical Trials in China, Country-Specific Clinical Trials

How China’s HGRAC Affects Global Rare Disease Trials

Posted on digi By digi

How China’s HGRAC Affects Global Rare Disease Trials The Impact of HGRAC Rules on Rare Disease Clinical Trials in China Introduction Rare disease clinical trials often depend on global collaboration, with sponsors seeking diverse genetic data and patient cohorts across regions. In China, the Human Genetic Resources Administration of China (HGRAC) plays a pivotal regulatory…

Read More “How China’s HGRAC Affects Global Rare Disease Trials” »

Clinical Trials in China, Country-Specific Clinical Trials